COMPANY

Callio Therapeutics

Keywords: antibody-drug conjugate oncology ADC cancer tumors CLIO-8221

Profile checked Oct 10, 2026

Timeline

Mar 19, 2026 Trial start Phase 1/Phase 2: Study in Advanced Solid Tumor Patients source ↗

Dec 31, 2027 (ESTIMATED) · Phase 1/Phase 2 · Study in Advanced Solid Tumor Patients · NCT07300943

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07300943	Study in Advanced Solid Tumor Patients	Phase 1/Phase 2	Recruiting	Mar 19, 2026	Dec 31, 2027 (estimated)